Nebulized Stem Cell EVs for Idiopathic Pulmonary Fibrosis

A new clinical trial registration was posted on ClinicalTrials.gov for a novel cell-free therapeutic approach using nebulized stem cell-derived extracellular vesicles to treat idiopathic pulmonary fibrosis. The study details indicate this is an early-phase investigation with safety as the primary endpoint.\n\nHealthcare providers treating IPF patients should note this emerging therapeutic approach in development. Clinical investigators may consider patient referral eligibility based on study criteria. This registration fulfills NIH/FDA clinical trial registration requirements for publicly sharing research information.